alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 51–75 of 355 studies published 2003 (page 3 of 15) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of these 355 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly

✓ Peer-reviewed alzhub usefulness score 61 out of 100. The New England journal of medicine 2003-04-01

There were 140,055 subjects in the 1998-1999 cohort and 146,328 in the 1999-2000 cohort, of which 55.5 percent and 59.7 percent, respectively, were immunized. 4 key findings →

Participants: 140,055 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Journal of clinical pharmacy and therapeutics 2003-02-01

Alzheimer's disease is characterized by a slow, progressive decline in cognitive function and behaviour. 4 key findings →

Participants: 42 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Differences Between Caregivers and Noncaregivers in Psychological Health and Physical Health: A Meta-Analysis

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Psychology and Aging 2003-06

This meta-analysis pooled 84 studies comparing family caregivers to demographically similar non-caregivers on stress, depression, well-being, physical health, and self-efficacy. 3 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source

Predictors of six-month survival among patients with dementia: an evaluation of hospice Medicare guidelines

✓ Peer-reviewed alzhub usefulness score 60 out of 100. The American journal of hospice & palliative care 2003-03-01

The goal of the present study was to assess the validity of the Medicare hospice eligibility guidelines for dementia patients, as well as identify predictors that could more accurately identify prognosis in dementia patients referred to hospice. 4 key findings →

Design: longitudinal study Participants: 245 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Homocysteine, white matter hyperintensities, and cognition in healthy elderly people

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Annals of neurology 2003-02-01

Hyperhomocysteinemia is associated with an increased risk of vascular disease, and recent results suggest that it also could increase the risk of dementia. 4 key findings →

Design: cross-sectional Participants: 1,241 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Depression as a risk factor for Alzheimer disease: the MIRAGE Study

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Archives of neurology 2003-05-01

Depression symptoms before the onset of AD are associated with the development of AD, even in families where first depression symptoms occurred more than 25 years before the onset of AD. 4 key findings →

Design: case-control study Participants: 1,953 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Clinical and organizational factors associated with feeding tube use among nursing home residents with advanced cognitive impairment

✓ Peer-reviewed alzhub usefulness score 60 out of 100. JAMA 2003-07-01

More than one third of severely cognitively impaired residents in US nursing homes have feeding tubes. 5 key findings →

Design: cross-sectional Participants: 186,835 Evidence: low

Full summary, score breakdown and related studies → Original source

Delirium symptoms in post-acute care: prevalent, persistent, and associated with poor functional recovery

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of the American Geriatrics Society 2003-01-01

The data from this study provide strong preliminary evidence that, in patients newly admitted to post-acute care facilities from acute care hospitals, delirium symptoms are prevalent, persistent, and associated with poor functional recovery. 4 key findings →

Design: cohort study Participants: 551 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging

✓ Peer-reviewed alzhub usefulness score 59 out of 100. NeuroImage 2003-02-01

To accurately predict the development of Alzheimer's disease (AD) at its predementia stage would be a major breakthrough from both therapeutic and research standpoints. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Longitudinal outcome of Parkinson's disease patients with psychosis

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Neurology 2003-06-01

Baseline data available from 59 patients enrolled in the PSYCLOPS (PSychosis and CLOzapine in PD Study) trial included age, age at onset of PD, duration of PD and psychosis, character of psychosis, medications, living setting, and scores for Mini-Mental State Examination (MMSE), Unified Parkinson's Disease Rating Scale, Hoehn and Yahr Scale, and Clinical Global Impression Scale. 4 key findings →

Design: longitudinal study Participants: 59 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Longitudinal driving performance in early-stage dementia of the Alzheimer type

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of the American Geriatrics Society 2003-10-01

This study provides longitudinal evidence for a decline in driving performance over time, primarily in early-stage DAT, and supports the need not only for driving assessments, but also for reevaluation of individuals with very mild and mild DAT. 3 key findings →

Design: longitudinal study Participants: 21 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Annals of internal medicine 2003-06-01

Study selection The authors developed eight key questions representing a logical chain between screening and improved health outcomes, along with eligibility criteria for admissible evidence for each question. 5 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Dementia as a risk factor for falls and fall injuries among nursing home residents

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Journal of the American Geriatrics Society 2003-09-01

Although most falls do not result in injury, the fact that residents with dementia fall more often than their counterparts without dementia leaves them with a higher overall risk of sustaining injurious falls over time. 2 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

CSF markers for incipient Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 57 out of 100. The Lancet. Neurology 2003-10-01

Early diagnosis of Alzheimer's disease (AD) is needed to initiate symptomatic treatment with acetylcholinesterase inhibitors, and will be of even greater significance if drugs aimed at slowing down the degenerative process, such as vaccination regimes and beta-secretase and gamma-secretase inhibitors, prove to affect AD pathology and to have clinical effect. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Archives of neurology 2003-12-01

Elevated CSF tau levels are associated with AD pathology and can help discriminate AD from other dementing disorders. 3 key findings →

Participants: 74 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed